Individual recombinant repeats of MUC16 display variable binding to CA125 antibodies

被引:3
|
作者
Wang, Chien-Wei [1 ,2 ]
Hanson, Eliza K. [1 ,2 ]
Minkoff, Lisa [2 ]
Whelan, Rebecca J. [1 ,2 ]
机构
[1] Univ Kansas, Dept Chem, Lawrence, KS 66045 USA
[2] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA
关键词
CA125; MUC16; ovarian cancer; tandem repeats; antibodies; affinity; OVARIAN-CANCER ANTIGEN; MONOCLONAL-ANTIBODIES; IMMUNORADIOMETRIC ASSAY; CA-125; ANTIGEN; BIOMARKERS; HE-4; PROTEIN; IDENTIFICATION; GLYCOPROTEIN; PREDICTION;
D O I
10.3233/CBM-220191
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Despite its importance in the clinical management of ovarian cancer, the CA125 biomarker - located on the mucin protein MUC16 - is still not completely understood. Questions remain about MUC16's function and structure, specifically the identity and location of the CA125 epitopes. OBJECTIVE: The goal of this study was to characterize the interaction of individual recombinant repeats from the tandem repeat domain of MUC16 with antibodies used in the clinical CA125 II test. METHODS: Using E. coli expression, we isolated nine repeats from the putative antigenic domain of CA125. Amino acid composition of recombinant repeats was confirmed by high-resolution mass spectrometry. We characterized the binding of four antibodies - OC125, M11, "OC125-like," and "M11-like" - to nine recombinant repeats using Western blotting, indirect enzyme-linked immunosorbent assay (ELISA), and localized surface plasmon resonance (SPR) spectroscopy. RESULTS: Each recombinant repeat was recognized by a different combination of CA125 antibodies. OC125 and "OC125-like" antibodies did not bind the same set of recombinant repeats, nor did M11 and "M11-like" antibodies. CONCLUSIONS: Characterization of the interactions between MUC16 recombinant repeats and CA125 antibodies will contribute to ongoing efforts to identify the CA125 epitopes and improve our understanding of this important biomarker.
引用
收藏
页码:85 / 94
页数:10
相关论文
共 50 条
  • [31] The role of the ovarian tumor marker CA125 (MUC16) in the suppression of human immune responses
    Belisle, JA
    Arens, JA
    Migneault, M
    Rancourt, C
    Felder, M
    Connor, J
    Patankar, MS
    JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) : 635 - 636
  • [32] MUC16/CA125, TNFα and IFNγ are co-expressed in malignant gynecologic neoplasms
    Morgado, Micaela
    Sutton, Margie N.
    Simmons, Mary
    Liu, Jinsong
    Lu, Zhen
    Papadopoulos, Pamela E.
    Bast, Robert C.
    Carson, Daniel D.
    CANCER RESEARCH, 2015, 75
  • [33] Molecular cloning of the CA125 ovarian cancer antigen - Identification as a new mucin, MUC16
    Yin, BWT
    Lloyd, KO
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (29) : 27371 - 27375
  • [34] MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis
    Theriault, Catherine
    Pinard, Maxime
    Comamala, Marina
    Migneault, Martine
    Beaudin, Julie
    Matte, Isabelle
    Boivin, Marianne
    Piche, Alain
    Rancourt, Claudine
    GYNECOLOGIC ONCOLOGY, 2011, 121 (03) : 434 - 443
  • [35] CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells
    Reinartz, Silke
    Failer, Sophie
    Schuell, Tina
    Wagner, Uwe
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (10) : 1558 - 1569
  • [36] Pre-clinical comparison of approaches to increasing the immunogenicity of CA125 (MUC16) DNA vaccines
    Ragupathi, Govind
    Koide, Fusataka
    Yin, Beatrice Wt
    Lloyd, Kenneth O.
    Hannaman, Drew
    Livingston, Philip O.
    CANCER RESEARCH, 2006, 66 (08)
  • [37] Integrated genomic analysis identifies PLEC1 as a molecular target of MUC16/CA125
    Blum, A.
    Tanner, E.
    Bisogna, M.
    Dao, F.
    Thapi, D.
    Spriggs, D.
    Levine, D.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S162 - S162
  • [38] Regulation of MUC16 (CA125) release in ovarian cancer cells by cytokines and growth factors.
    Spriggs, E
    Spriggs, C
    Thapi, D
    Awtry, C
    Spriggs, DR
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9139S - 9140S
  • [39] Pathobiological Implications of MUC16/CA125 Expression in Intrahepatic Cholangiocarcinoma-Mass Forming Type
    Higashi, Michiyo
    Yamada, Norishige
    Yokoyama, Seiya
    Kitamoto, Sho
    Tabata, Kazuhiro
    Koriyama, Chihaya
    Batra, Surinder K.
    Yonezawa, Suguru
    PATHOBIOLOGY, 2012, 79 (02) : 101 - 106
  • [40] Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion
    Rao, Thapi D.
    Tian, Huasong
    Ma, Xun
    Yan, Xiujun
    Thapi, Sahityasri
    Schultz, Nikolaus
    Rosales, Nestor
    Monette, Sebastien
    Wang, Amy
    Hyman, David M.
    Levine, Douglas A.
    Solit, David
    Spriggs, David R.
    PLOS ONE, 2015, 10 (05):